Is LUV Stock a Buy, Sell or Hold?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation…
Sell
26
IGMS Quote, Financials, Valuation and Earnings
Last price:
$1.16
Seasonality move
:
7.39%
Day range:
$1.12 - $1.23
52-week range:
$1.11 - $22.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
27.78x
P/B ratio:
1.53x
Volume:
135K
Avg. volume:
193.3K
1-year change:
-86.54%
Market cap:
$73.5M
Revenue:
$2.7M
EPS (TTM):
-$3.24
Analysts' Opinion
-
Consensus RatingIGM Biosciences has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 6 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $2.13, IGM Biosciences has an estimated upside of 72.76% from its current price of $1.23.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing -21.95% downside risk from its current price of $1.23.
Fair Value
-
According to the consensus of 7 analysts, IGM Biosciences has 72.76% upside to fair value with a price target of $2.13 per share.
IGMS vs. S&P 500
-
Over the past 5 trading days, IGM Biosciences has underperformed the S&P 500 by -1.59% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
IGM Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IGM Biosciences revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter IGM Biosciences reported revenues of $412K.
Earnings Growth
-
IGM Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter IGM Biosciences reported earnings per share of -$0.61.
Enterprise value:
-110.3M
EV / Invested capital:
--
Price / LTM sales:
27.78x
EV / EBIT:
--
EV / Revenue:
-41.16x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.69x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-57.38%
Net Income Margin (TTM):
-7308.51%
Return On Equity:
-159.45%
Return On Invested Capital:
-159.45%
Operating Margin:
-9461.17%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $2.1M | $2.7M | $651K | $412K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$228M | -$263.5M | -$208.6M | -$65.1M | -$39M | |
| EBITDA | -$221.9M | -$255.2M | -$199.5M | -$62.9M | -$36.6M | |
| Diluted EPS | -$5.37 | -$4.78 | -$3.24 | -$0.98 | -$0.61 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $373.3M | $240.7M | $438.4M | $347.6M | $193.6M | |
| Total Assets | $408.6M | $298.1M | $513.5M | $423.4M | $265.7M | |
| Current Liabilities | $17.2M | $27.8M | $44.7M | $42.5M | $37.6M | |
| Total Liabilities | $26.8M | $53.2M | $226.2M | $220.2M | $217.5M | |
| Total Equity | $381.8M | $244.9M | $287.3M | $203.2M | $48.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.9M | -$192.2M | -$153M | -$48M | -$34.8M | |
| Cash From Investing | -$225.6M | $68.4M | $64.2M | -$14.7M | $18M | |
| Cash From Financing | $219.4M | $115.1M | $2.4M | $402K | $420K | |
| Free Cash Flow | -$16.1M | -$204.6M | -$158.8M | -$49.5M | -$35.7M | |
IGMS
Sector
Market Cap
$73.5M
$35.9M
Price % of 52-Week High
5.47%
43.21%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-86.54%
-43.29%
Beta (5-Year)
0.579
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.23
200-day SMA
Sell
Level
$8.26
Bollinger Bands (100)
Sell
Level
0.69 - 9.21
Chaikin Money Flow
Sell
Level
-9.3M
20-day SMA
Sell
Level
$1.26
Relative Strength Index (RSI14)
Sell
Level
40.11
ADX Line
Sell
Level
41.31
Williams %R
Neutral
Level
-38.4615
50-day SMA
Sell
Level
$1.39
MACD (12, 26)
Sell
Level
-0.14
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
28.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.2293)
Sell
CA Score
(Annual)
Level (-3.8125)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (5.3539)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Stock Forecast FAQ
In the current month, IGMS has received 0 Buy ratings 6 Hold ratings, and 1 Sell ratings. The IGMS average analyst price target in the past 3 months is $2.13.
-
Where Will IGM Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that IGM Biosciences share price will rise to $2.13 per share over the next 12 months.
-
What Do Analysts Say About IGM Biosciences?
Analysts are divided on their view about IGM Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that IGM Biosciences is a Buy and believe this share price will drop from its current level to $3.00.
-
What Is IGM Biosciences's Price Target?
The price target for IGM Biosciences over the next 1-year time period is forecast to be $2.13 according to 7 Wall Street analysts, 0 of them rate the stock a Buy, 1 rates the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is IGMS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IGM Biosciences is a Hold. 6 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of IGMS?
You can purchase shares of IGM Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IGM Biosciences shares.
-
What Is The IGM Biosciences Share Price Today?
IGM Biosciences was last trading at $1.16 per share. This represents the most recent stock quote for IGM Biosciences. Yesterday, IGM Biosciences closed at $1.23 per share.
-
How To Buy IGM Biosciences Stock Online?
In order to purchase IGM Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
43
MNPR alert for Apr 3
Monopar Therapeutics [MNPR] is down 10.04% over the past day.
Buy
75
BKTI alert for Apr 3
BK Technologies [BKTI] is down 7.68% over the past day.
Sell
34
SWTX alert for Apr 3
SpringWorks Therapeutics [SWTX] is down 7.29% over the past day.
